<div id="readability-page-1"><p><span>Organogenesis (NASDAQ:ORGO - Get Free Report)</span>'s stock had its &#34;buy&#34; rating reissued by analysts at BTIG Research in a research note issued on Friday,Benzinga reports. They presently have a $9.00 price objective on the stock. BTIG Research's price objective would suggest a potential upside of 52.39% from the stock's current price.</p><div><p><span></span><span>Get <strong>Organogenesis</strong> alerts:</span></p></div><p>A number of other equities research analysts have also weighed in on the stock. Weiss Ratings  restated a &#34;sell (d+)&#34; rating on shares of Organogenesis in a report on Monday. Wall Street Zen upgraded Organogenesis from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Saturday, November 8th. Two research analysts have rated the stock with a Buy rating, one  has assigned  a Hold rating and one  has given a Sell rating to the company's stock. According to data from MarketBeat.com, Organogenesis  has a consensus rating of &#34;Hold&#34; and an average target price of $8.00.</p><p><b>View Our Latest Research Report on Organogenesis</b></p><h2>Organogenesis Trading Up 2.7%</h2><p>ORGO opened at $5.91 on Friday. The firm has a market cap of $749.53 million, a P/E ratio of -49.22 and a beta of 1.47. Organogenesis has a 12 month low of $2.61 and a 12 month high of $7.08. The stock has a 50-day moving average of $5.03 and a 200 day moving average of $4.59. The company has a current ratio of 3.32, a quick ratio of 2.88 and a debt-to-equity ratio of 0.01. </p><p>Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.18 earnings per share for the quarter, topping analysts' consensus estimates of $0.07 by $0.11. The company had revenue of $150.86 million for the quarter, compared to analyst estimates of $134.10 million. Organogenesis had a negative net margin of 1.30% and a positive return on equity of 4.01%.  As a group, research analysts forecast that  Organogenesis will post -0.07 EPS for the current year. </p><h2>Insider Activity</h2><p>In related news, Director Glenn H. Nussdorf sold 200,000 shares of Organogenesis stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $5.14, for a total transaction of $1,028,000.00. Following the completion of the sale, the director owned 2,565,591 shares of the company's stock, valued at $13,187,137.74. The trade was a 7.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 500,000 shares of company stock valued at $2,620,120 over the last three months. Company insiders own  33.00% of the company's stock. </p><h2>Institutional Investors Weigh In On Organogenesis</h2><p>Several hedge funds have recently added to or reduced their stakes in ORGO. First Light Asset Management LLC lifted its holdings in  Organogenesis by 10.6% in the third quarter. First Light Asset Management LLC now owns 7,497,911 shares of the company's stock valued at $31,641,000 after acquiring an additional 720,748 shares during the period.  Assenagon Asset Management S.A. increased its holdings in shares of  Organogenesis by 69.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 4,854,942 shares of the company's stock valued at $20,488,000 after purchasing an additional 1,997,038 shares in the last quarter.  Vanguard Group Inc. lifted its stake in shares of  Organogenesis by 23.4% in the 1st quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company's stock valued at $19,144,000 after purchasing an additional 841,618 shares during the period.  Acadian Asset Management LLC lifted its stake in shares of  Organogenesis by 3.9% in the 2nd quarter. Acadian Asset Management LLC now owns 2,424,363 shares of the company's stock valued at $8,862,000 after purchasing an additional 91,118 shares during the period.  Finally, Driehaus Capital Management LLC purchased a new stake in  Organogenesis during the first quarter worth $7,756,000. 49.57% of the stock is owned by hedge funds and other institutional investors. </p><h2>Organogenesis Company Profile</h2> (Get Free Report)<p>Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company's product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.  </p><p>Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Organogenesis</li><li>Do you know what Amazon is planning for January 1?</li><li>$100 Trillion “AI Metal” Found in American Ghost Town</li><li>Washington prepares for war</li><li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li><li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Organogenesis Right Now?</h2><p>Before you consider Organogenesis, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organogenesis wasn't on the list.</p><p>While Organogenesis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ORGO

<p>BTIG Research reaffirmed a "buy" rating for Organogenesis (NASDAQ:ORGO) with a target price of $9.00, suggesting a potential upside of 52.39%. Other analysts have mixed ratings, with a consensus "Hold" and an average target price of $8.00. Organogenesis reported better-than-expected quarterly earnings, with $0.18 EPS and $150.86 million revenue. Insider activity includes significant stock sales, and institutional investors have adjusted their stakes in the company.</p>

Organogenesis' (ORGO) "Buy" Rating Reiterated at BTIG Research